Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

from AUAUniversity · host American Urological Association

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events. Educational grants provided by the following corportations: AstraZeneca, Bristol-Myers Squibb, Genentech, Merck

Episode metadata supplied by the publisher feed · Published Mar 31, 2017

Embed this episode

Attribution link and audio player

NOW PLAYING

Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

0:00 55:09

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AUAUniversity?

This episode is 55 minutes long.

When was this AUAUniversity episode published?

This episode was published on March 31, 2017.

Can I download this AUAUniversity episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!